These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18598191)

  • 21. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
    Torti C; Quiros-Roldan E; Keulen W; Scudeller L; Lo Caputo S; Boucher C; Castelli F; Mazzotta F; Pierotti P; Been-Tiktak AM; Buccoliero G; De Gennaro M; Carosi G; Tinelli C;
    J Infect Dis; 2003 Jul; 188(2):194-201. PubMed ID: 12854073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
    Vingerhoets J; Nijs S; Tambuyzer L; Hoogstoel A; Anderson D; Picchio G
    Antivir Ther; 2012; 17(8):1571-9. PubMed ID: 22869341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique.
    Maldonado F; Biot M; Roman F; Masquelier C; Anapenge M; Bastos R; Chuquela HC; Arendt V; Schmit JC; Zachariah R
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):607-12. PubMed ID: 18804251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml.
    Waters L; Mandalia S; Asboe D
    AIDS; 2006 Mar; 20(5):778-9. PubMed ID: 16514311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluating the therapeutic care of HIV infection in Tunisia].
    Jlizi A; Slim A; Benammar Elgaaied A; Ben Rejab S; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M
    Tunis Med; 2008 Jun; 86(6):534-9. PubMed ID: 19216443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.
    Houssaini A; Assoumou L; Miller V; Calvez V; Marcelin AG; Flandre P
    PLoS One; 2013; 8(3):e59014. PubMed ID: 23555613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment.
    Prosperi MC; Altmann A; Rosen-Zvi M; Aharoni E; Borgulya G; Bazso F; Sönnerborg A; Schülter E; Struck D; Ulivi G; Vandamme AM; Vercauteren J; Zazzi M;
    Antivir Ther; 2009; 14(3):433-42. PubMed ID: 19474477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations.
    Wang K; Samudrala R; Mittler JE
    J Infect Dis; 2004 Dec; 190(11):2055-6; author reply 2056. PubMed ID: 15529272
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypic antiretroviral drug resistance testing at low viral loads in the UK.
    Cane PA; Kaye S; Smit E; Tilston P; Kirk S; Shepherd J; Hopkins M; Zhang H; Geretti AM
    HIV Med; 2008 Oct; 9(8):673-6. PubMed ID: 18557948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The power of simplicity.
    Lange J
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():15-9. PubMed ID: 14617399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
    Charpentier C; Laureillard D; Sodqi M; Si-Mohamed A; Karmochkine M; Bélec L; Weiss L; Piketty C
    J Clin Virol; 2008 Oct; 43(2):212-5. PubMed ID: 18760662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.